# Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects

> **NCT05492630** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 138 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** HEC73077 tablets
- **DRUG:** HEC73077 placebo tablets

## Key facts

- **NCT ID:** NCT05492630
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-24
- **Primary completion:** 2023-01-04
- **Final completion:** 2023-01-04
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05492630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05492630, "Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05492630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*